Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer
Nautilus Biotechnology (NASDAQ: NAUT) has appointed Ken Suzuki as Chief Marketing Officer. Suzuki, a 25-year veteran from Agilent Technologies, brings extensive experience in mass spectrometry and proteomics to Nautilus, a company developing a single-molecule protein analysis platform. This strategic hire comes as Nautilus prepares to launch its Proteome Analysis Platform.
Suzuki's background includes leadership roles in Agilent's Mass Spectrometry division, Strategic Program Office, and Spectroscopy department. His expertise spans marketing, product development, finance, and R&D in the life sciences sector. Nautilus CEO Sujal Patel expressed enthusiasm about Suzuki's potential impact on bringing the company's platform to researchers worldwide.
Nautilus Biotechnology (NASDAQ: NAUT) ha nominato Ken Suzuki come Chief Marketing Officer. Suzuki, un veterano con 25 anni di esperienza in Agilent Technologies, porta con sé un'ampia esperienza in spettrometria di massa e proteomica a Nautilus, una compagnia che sviluppa una piattaforma per l'analisi dei proteini a molecole singole. Questa assunzione strategica avviene mentre Nautilus si prepara a lanciare la sua Proteome Analysis Platform.
Il background di Suzuki include ruoli dirigenziali nella divisione di Spettrometria di Massa di Agilent, nell'Ufficio dei Programmi Strategici e nel dipartimento di Spettroscopia. La sua esperienza spazia dal marketing, sviluppo prodotto, finanza e R&D nel settore delle scienze della vita. Il CEO di Nautilus Sujal Patel ha espresso entusiasmo riguardo al potenziale impatto di Suzuki nel portare la piattaforma dell'azienda ai ricercatori in tutto il mondo.
Nautilus Biotechnology (NASDAQ: NAUT) ha nombrado a Ken Suzuki como Director de Marketing. Suzuki, un veterano de 25 años de Agilent Technologies, trae consigo una amplia experiencia en espectrometría de masas y proteómica a Nautilus, una empresa que desarrolla una plataforma de análisis de proteínas de molécula única. Esta contratación estratégica se produce mientras Nautilus se prepara para lanzar su Proteome Analysis Platform.
El historial de Suzuki incluye roles de liderazgo en la división de Espectrometría de Masas de Agilent, en la Oficina de Programas Estratégicos y en el departamento de Espectroscopia. Su experiencia abarca marketing, desarrollo de productos, finanzas e I+D en el sector de las ciencias de la vida. El CEO de Nautilus, Sujal Patel, expresó entusiasmo por el impacto potencial de Suzuki en llevar la plataforma de la compañía a los investigadores de todo el mundo.
노틸러스 바이오테크놀로지 (NASDAQ: NAUT)는 켄 스즈키를 최고 마케팅 책임자로 임명했습니다. 스즈키는 아질런트 테크놀로지스에서 25년의 경력을 가진 전문가로, 노틸러스에 단일 분자 단백질 분석 플랫폼을 개발하는 데 풍부한 질량 분석 및 단백질체학 경험을 제공합니다. 이 전략적 채용은 노틸러스가 단백질체 분석 플랫폼을 출시할 준비를 하는 시점과 일치합니다.
스즈키의 경력에는 아질런트의 질량 분석 부서, 전략 프로그램 사무소 및 분광학 부서에서의 리더십 역할이 포함됩니다. 그의 전문성은 생명 과학 분야에서 마케팅, 제품 개발, 재무 및 연구 개발(R&D)을 아우릅니다. 노틸러스의 CEO 수잘 파텔은 스즈키가 회사의 플랫폼을 전 세계 연구자들에게 전달하는 데 미칠 긍정적인 영향에 대해 기대감을 표명했습니다.
Nautilus Biotechnology (NASDAQ: NAUT) a nommé Ken Suzuki en tant que Directeur Marketing. Suzuki, un vétéran de 25 ans d'Agilent Technologies, apporte une vaste expérience en spectrométrie de masse et en protéomique à Nautilus, une entreprise qui développe une plateforme d'analyse de protéines à molécule unique. Cette embauche stratégique intervient alors que Nautilus se prépare à lancer sa Proteome Analysis Platform.
Le parcours de Suzuki comprend des rôles de leadership dans la division de Spectrométrie de Masse d'Agilent, au Bureau des Programmes Stratégiques et dans le département de Spectroscopie. Son expertise couvre le marketing, le développement de produits, les finances et la R&D dans le secteur des sciences de la vie. Le PDG de Nautilus, Sujal Patel, a exprimé son enthousiasme quant à l'impact potentiel de Suzuki pour amener la plateforme de l'entreprise aux chercheurs du monde entier.
Nautilus Biotechnology (NASDAQ: NAUT) hat Ken Suzuki zum Chief Marketing Officer ernannt. Suzuki, ein 25-jähriger Veteran von Agilent Technologies, bringt umfangreiche Erfahrung in der Massenspektrometrie und Proteomik zu Nautilus, einem Unternehmen, das eine Plattform zur Analyse von Einzelmolekül-Proteinen entwickelt. Diese strategische Einstellung erfolgt, während Nautilus sich auf die Einführung seiner Proteome Analysis Platform vorbereitet.
Suzukis Werdegang umfasst Führungsrollen in der Massenspektrometrie-Abteilung von Agilent, im Strategischen Programm Büro und im Bereich Spektroskopie. Sein Fachwissen reicht von Marketing über Produktentwicklung, Finanzen bis hin zu F&E im Bereich der Lebenswissenschaften. Der CEO von Nautilus, Sujal Patel, äußerte sich begeistert über Suzukis potenziellen Einfluss, die Plattform des Unternehmens weltweit zu Forschern zu bringen.
- Appointment of industry veteran Ken Suzuki as Chief Marketing Officer
- Suzuki brings 25 years of experience from Agilent Technologies, a leader in mass spectrometry
- Strategic hire to support the launch of Nautilus' Proteome Analysis Platform
- Suzuki's expertise spans marketing, product development, finance, and R&D in life sciences
- None.
Industry veteran brings multidisciplinary expertise leading Mass Spectrometry division at Agilent Technologies to a company building a platform to power next-generation proteomics
SEATTLE, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for comprehensively quantifying the proteome, today announced the appointment of Kentaro (Ken) Suzuki as Chief Marketing Officer.
Mr. Suzuki joins Nautilus after 25 years in product and marketing leadership roles at Agilent Technologies, most recently serving as Vice President and General Manager of Agilent’s Mass Spectrometry division. He has held numerous leadership positions at Agilent, including in the Strategic Program Office and Certified Pre-Owned Instruments, CrossLab Services and Support, and Spectroscopy.
“Ken is an exciting and timely addition to our executive team here at Nautilus and I could not be more excited about working closely with him to get our platform into the hands of researchers around the world,” said Sujal Patel, co-founder and Chief Executive Officer of Nautilus. “Ken is a seasoned, deeply strategic leader who has driven numerous cutting-edge advances in the field of proteomics. He will provide critical expertise as we prepare to bring our Proteome Analysis Platform to market for use by mass spectrometry users and broader researchers alike.”
Mr. Suzuki’s track record in the life sciences and technology sector spans nearly three decades of innovation across marketing, product, finance, and research and development. Previously, he held roles in application and sales at Takeda Pharmaceuticals in Tokyo, Japan, and in finance at Hewlett-Packard (HP) before contributing to the founding of Agilent. Mr. Suzuki received his M.B.A. from the Haas School of Business at the University of California, Berkeley, and his B.S. in Biological Engineering from Cornell University.
“As proteomics rapidly and rightfully gains recognition as the next frontier of biology that will revolutionize how we treat and manage disease, our industry will need next-generation technologies that complement our established methods,” said Ken Suzuki. “After years working to improve traditional methods of characterizing the proteome, I’m excited to extend beyond the scope of mass spectrometry and join Nautilus in pioneering a novel platform that holds the potential to unlock the proteome at full-scale.”
He will be based in Nautilus’ research and development headquarters in the San Francisco Bay Area.
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle and its research and development headquarters in the San Francisco Bay Area, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.
Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding Nautilus’ expectations regarding the company’s business operations, financial performance and results of operations; expectations with respect to any revenue timing or projections, expectations with respect to the development required for and the timing of the launch of Nautilus’ product platform and full commercial availability, the functionality and performance of Nautilus’ product platform, its potential impact on providing proteome access, pharmaceutical development and drug discovery, expanding research horizons, and enabling scientific explorations and discovery, and the present and future capabilities and limitations of emerging proteomics technologies. These statements are based on numerous assumptions concerning the development of Nautilus’ products, target markets, and other current and emerging proteomics technologies, and involve substantial risks, uncertainties and other factors that may cause actual results to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that could materially affect the accuracy of Nautilus’ assumptions and its ability to achieve the forward-looking statements set forth in this press release include (without limitation) the following: Nautilus’ product platform is not yet commercially available and remains subject to significant scientific and technical development, which is inherently challenging and difficult to predict, particularly with respect to highly novel and complex products such as those being developed by Nautilus. Even if our development efforts are successful, our product platform will require substantial validation of its functionality and utility in life science research. In the course of Nautilus’ scientific and technical development and associated product validation and commercialization, we may experience material delays as a result of unanticipated events. We cannot provide any guarantee or assurance with respect to the outcome of our development, collaboration, and commercialization initiatives or with respect to their associated timelines. For a more detailed description of additional risks and uncertainties facing Nautilus and its development efforts, investors should refer to the information under the caption “Risk Factors” in our Annual Report on Form 10-K as well as in our Quarterly Report on Form 10-Q filed for the quarter ended June 30, 2024 and our other filings with the SEC. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, Nautilus disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Media Contact
press@nautilus.bio
Investor Contact
investorrelations@nautilus.bio
A photo accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/c31047a4-8653-4881-855a-6dfc6983c8ba
FAQ
Who is Nautilus Biotechnology's new Chief Marketing Officer?
What is Nautilus Biotechnology's (NAUT) main product focus?
How might Ken Suzuki's appointment impact Nautilus Biotechnology (NAUT)?
What is Ken Suzuki's background before joining Nautilus Biotechnology (NAUT)?
